Curative effect analysis of active circulating hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for platinum-sensitive relapsed ovarian cancer
Objective To investigate the efficacy of active circulating hyperthermic intraperitoneal chemotherapy (HIPEC) combined with cytoreductive surgery (CRS) in the treatment of platinum-sensitive relapsed ovarian cancer (PSR).Methods A total of 93 patients with PSR ovarian cancer were selected from January 2018 to January 2021 in Ordos Central Hospital. The patients were divided into two groups by random number table method:observation group (47 cases) and control group (46 cases). The control group received CRS and TP chemotherapy after surgery,while the observation group received CRS and active circulating HIPEC after surgery. The efficacy of the patients after 3 courses of treatment was evaluated,and the cellular immune function ( CD4+,CD8+,CD4+/CD8+) and tumor glycoprotein indexes[Serum human epididymal protein 4 ( HE4 ),glycoprotein 125 ( CA125 ),vascular endothelial growth factor (VEGF)]were detected. The safety of treatment was observed and the survival of patients was analyzed. Results The overall response rate (ORR) in observation group[85.11％ (40/47)]was higher than that in control group[65.22％(30/46)],and the difference was statistically significant (P<0.05). After treatment,the levels of CD4+,CD4+/CD8+were increased,and the levels of CD8+,VEGF,CA125 and HE4 were decreased in both groups (P<0.05). The levels of CD4+,CD4+/CD8+in observation group were higher than those in control group,and the levels of CD8+,VEGF,CA125 and HE4 were lower than those in control group (P<0.05). There were no significant difference in the incidence of adverse drug reactions such as nausea and vomiting,thrombocytopenia,leukopenia,fever and myelosuppression between two groups ( P>0.05 ) . The average survival time of observation group and control group were (55.30±0.88) months and (42.45±2.92) months,respectively. By Log-Rank test,the survival curves of the two groups were significantly different (Log-Rank x2=4.030,P=0.045). Conclusion Active circulating HIPEC combined with CRS can improve the efficacy of PSR ovarian cancer,improve cellular immunity,reduce tumor glycoprotein expression,and do not increase adverse reactions,so it is safe and effective.
万方数据
